Crescent Biopharma (CBIO) FCF Margin (2013 - 2026)

Crescent Biopharma (CBIO) reported FCF Margin of 870.74% for Q1 2026, up 95.99% quarter-over-quarter from 21695.8% in Q2 2022.

Crescent Biopharma (CBIO) FCF Margin (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has 8 years of FCF Margin data on file, last reported at 870.74% in Q1 2026.

FCF Margin for Q1 2026 came in at 870.74%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 6709.05% (changed N/A YoY), and the FY2025 annual result was 659.45%, changed N/A from the prior year.
FCF Margin grew to 870.74% in Q1 2026 per CBIO's latest filing, from 21695.8% in the prior quarter.
Over five years, FCF Margin peaked at 870.74% in Q1 2026 and troughed at 21695.8% in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-3.98%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	43.35%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Crescent Biopharma	486.92 Mn	297.76 Mn	-	-870.74%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-870.74%
Jun 30, 2022	-21,695.80%
Dec 31, 2021	-72,675.25%
Sep 30, 2021	-19,582.49%
Jun 30, 2021	-9,589,105.63%
Mar 31, 2021	-1,338.62%
Dec 31, 2020	-5,980.21%
Sep 30, 2020	-1,150.00%
Mar 31, 2020	-38.98%
Sep 30, 2016	-40,330.17%
Dec 31, 2015	-19,676.90%
Sep 30, 2015	38,178.15%
Jun 30, 2015	-31.74%
Jun 30, 2014	60.77%
Dec 31, 2013	-7,205.59%
Sep 30, 2013	-6,521.65%
Jun 30, 2013	-4,959.27%
Mar 31, 2013	-101.99%